The conversation discusses the use of 12.5mg cyproterone every other day for hair loss. There's a concern about reducing testosterone potentially increasing DHT and negatively affecting hair.
A 22-year-old is experiencing hair thinning despite using finasteride and dutasteride, and plans to try minoxidil next. The user is frustrated with the lack of results and is considering drastic measures if the situation doesn't improve.
The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.
The user is experiencing side effects from Dutasteride 0.5 mg and is considering reducing its frequency or switching back to Finasteride, while continuing with Minoxidil 2.5 mg to preserve their hairline. They are unsure if the increased Minoxidil dose is sufficient for regrowth.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
A user has been using finasteride and minoxidil for hair loss without success and is considering switching to dutasteride. They are concerned about low DHT levels and are seeking advice on how to implement dutasteride effectively.
Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.
Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.
HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.
A 25-year-old switched from finasteride to dutasteride, experiencing significant hair regrowth and improved hair quality after 6 months, taking it three times a week. The user stopped finasteride entirely, citing dutasteride's longer half-life as more effective.
A 20-year-old is considering switching from finasteride to dutasteride during a steroid cycle to better manage hair loss, then returning to finasteride afterward. They are concerned about the risks of post-finasteride syndrome from frequently changing medications.
The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.
A user found a red light cap from China with good specifications for hair loss treatment, priced at €480. They seek opinions on its legitimacy and quality, especially from those with experience ordering from AliExpress.
The conversation discusses concerns about the effectiveness of RU58841 due to high temperatures during delivery. A user reassures that the heat will not affect its efficacy.
Koshine KX-826 has different versions, and the green version uses a plant-based carrier that may be less irritating for those sensitive to propylene glycol. Users report irritation with some versions of KX-826.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.
The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.
Shiseido's S-DSC Hair Multiplication Treatment in Japan is available to foreigners but is expensive and not very effective. Despite past disappointments, there is hope for future treatments with more options in development beyond Minoxidil and Finasteride.
A user underwent a hair transplant at Moart Clinic in Seoul, receiving 1100 grafts in the crown area after Dutasteride and oral Minoxidil failed to improve a stubborn bald spot. The procedure was successful, with minimal pain and good post-op recovery, costing $6900 USD before a tax refund.
Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.
The conversation is about starting a Discord group for people using KX-826 as their only treatment for hair loss, excluding those who are not serious or use multiple treatments. Someone agrees with the idea but mentions "GP :3," which is unclear.
A user is experimenting with creating a DIY oral Dutasteride solution using raw powder, MCT oil, and Vitamin E to reduce costs. Others discuss their experiences with similar methods and the challenges of sourcing and testing Dutasteride.
The user experienced hair thinning from chromium and alpha lipoic acid supplements, which stopped after discontinuing them. Someone mentioned this could be telogen effluvium, a temporary condition.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
The conversation is about the preference for using a derma stamp over a derma roller for hair loss treatment, with users discussing its efficiency, needle material, replacement frequency, and personal experiences. Specific treatments mentioned include microneedling with a derma stamp.